A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674
This study is recruiting at 9 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ovarian Cancer, Epithelial
- Gastric Cancer
- GastroEsophageal Junction (GEJ) Cancer
- Head and Neck Squamous Cell Carcinoma
- Metastatic or Unresectable Melanoma
- Non-small Cell Lung Cancer (NSCLC)
- Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Malignant Pleural Mesothelioma (MPM)
- Triple Negative Breast Cancer (TNBC)
- Metastatic Urothelial Carcinoma
- Cervical Cancer
- Diffuse Large B Cell Lymphoma (DLBCL)
- Richter Transformation
- Microsatellite Stable Colorectal Carcinoma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Nurix Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- September 9, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- University of Southern California · Los Angeles, CA
- University of California, San Francisco · San Francisco, CA
Colorado · 1
- University of Colorado School of Medicine · Aurora, CO
Illinois · 1
- University of Chicago · Chicago, IL
North Carolina · 1
- University of North Carolina · Chapel Hill, NC
Oklahoma · 1
- University of Oklahoma · Oklahoma City, OK
Texas · 1
- MD Anderson Cancer Center · Houston, TX
Virginia · 1
- University of Virginia · Charlottesville, VA
Washington · 1
- Fred Hutchinson Cancer Center · Seattle, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.